Prokarium

Bladder Cancer Market Insight Series We're shedding light on crucial challenges in the fight against bladder cancer. Bladder cancer has the highest lifetime treatment costs. It also has one of the highest recurrence rates among all cancers. #BladderCancer #Oncology

Bladder Cancer Market Insight Series This week, we are focusing on prevalence and the standard-of-care. Understanding survival rates reveals critical gaps in the lack of therapeutic options for patients living with bladder cancer.

🚀Bladder Cancer Market Insight Series This week, we're diving into critical statistics about bladder cancer diagnosis in the US. Did you know that bladder cancer is the 6th most common? Understanding these numbers is vital for driving innovation and improving patient outcomes.

Marc Biarnes Carrera, Head of Discovery, Synthetic Biology, will be presenting a poster at SEED on Wednesday the 26th June.

Prokarium is proud to share our latest article, "Programmable Cancer Treatments: Engineering Biology Approaches for Living Cures", highlighting the vast potential of hashtag#syntheticbiology in revolutionizing hashtag#cancertherapy. Full article here : lnkd.in/eFZerP7F

🫧 May was Bladder Cancer Awareness Month 🫧 The team took part in Fight Bladder Cancer's Bubbles for Bladder Cancer initiative. @Prokarium is currently enrolling patients in our PARADIGM-1 clinical trial in the US for the treatment of non-muscle invasive bladder cancer.

Prokarium announces the promotion of Livija Deban to Chief Scientific Officer: prokarium.com/prokarium-prom…. Previously serving as VP of Research at Prokarium, Dr. Deban will continue to drive the development of the company’s immuno-oncology portfolio.

Prokarium announces the appointment of Thomas Eldered as Chairman of the Board: bit.ly/3FlIlLZ. With 30+ years of experience, including co-founding & managing @RecipharmAB, one of the 5 largest CDMOs in the world, Thomas will be a valuable addition to the Prokarium team.

Prokarium today announced the appointment of Kristen Albright as new CEO: bit.ly/3734xKU. As Prokarium accelerates its drug development efforts within #oncology, Kristen brings extensive financing & strategic leadership experience that will propel the company forward.

Engineering Biology is the cutting edge of #biotech – and many @BIA_UK members are breaking boundaries in this space. Check out this video featuring @synthace @Prokarium and @GreenBioLtd - bit.ly/2AelxhY #synbio

@Prokarium's $10 mio investment featured in @FiercePharma - see fiercepharma.com/vaccines/proka…

Toward Killing Cancer with Bacteria | The Scientist Magazine® the-scientist.com/?articles.view…

Rocky M. Cranenburgh| Prokarium Ltd | UK | Vaccines 2014 | OMICS Interna... youtu.be/ZrR7l9VSPc4 vía @YouTube